Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
371 hedge funds and large institutions have $2.39B invested in Catalyst Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 126 increasing their positions, 127 reducing their positions, and 31 closing their positions.
353% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $547K
132% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 31
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
17% more capital invested
Capital invested by funds: $2.04B → $2.39B (+$350M)
10% more funds holding
Funds holding: 336 → 371 (+35)
1% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 127
0.91% less ownership
Funds ownership: 81.91% → 81% (-0.91%)
Top Buyers
| 1 |
Fundsmith LLP
London,
United Kingdom
|
+$48.4M |
| 2 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$14.8M |
| 3 |
Swedbank
Stockholm,
Sweden
|
+$13.9M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$12.5M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$8.31M |
Top Sellers
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$47.3M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$44.9M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18.6M |
| 4 |
BlackRock
New York
|
-$14M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$12.1M |
CPRX Hedge Fund Activity: Q1 2025 in Review
371 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2025, worth a combined $2.39B — up 17% from $2.04B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new CPRX positions and 31 closed out — a net gain of 41 holders — while 126 added to existing stakes and 127 trimmed.
The largest buyer was Fundsmith LLP, opening a new position worth an estimated $48.4M. The largest seller was Pacer Advisors, cutting an estimated $47.3M.
- 371 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2025, up from 336 in Q4 2024.
- Funds reported $2.39B of Catalyst Pharmaceutical stock for Q1 2025, up 17% quarter-over-quarter.
- 72 funds opened new Catalyst Pharmaceutical positions in Q1 2025 and 31 closed out, a net change of +41 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2025 was Fundsmith LLP, an estimated $48.4M added.
- The largest Catalyst Pharmaceutical seller in Q1 2025 was Pacer Advisors, an estimated $47.3M sold.
Based on aggregated 13F filings for Q1 2025.